Clinical Trials Browser

Advanced Malignancies

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Solid Malignancies

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Carcinoma, Renal Cell

Advanced Solid Tumors

Carcinoma, Carcinoma, Hepatocellular

Breast Neoplasms, Triple Negative Breast Neoplasms

Liposarcoma, Sarcoma

Carcinoma, Renal Cell

Advanced Solid Tumor

Carcinoma, Non-Small-Cell Lung

Advanced Biliary Tract Cancer

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Small Cell Lung Carcinoma

Carcinoma, Transitional Cell

Squamous Cell Carcinoma of Head and Neck

Uterine Cervical Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Prostatic Neoplasms

Endometrial Neoplasms

Clinical Trials

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

SAPPHIRE

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

Sitravatinib in Metastatic Breast Cancer

Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

BTC-BGB

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

SPARK

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

SNOW

ITTACC

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma